MK-677 (Ibutamoren) is an orally active growth hormone secretagogue studied in preclinical and clinical research. Patients can request a telehealth evaluation through the TelosRX Telehealth Portal to discuss compounded access.
What Is MK-677?
MK-677 (Ibutamoren) is a non-peptide compound that mimics ghrelin signaling. It is studied in research for growth hormone axis activity.
MK-677 is not an FDA-approved drug. It is available through compounding pharmacies under valid prescription.
Common Discussion Points
Patients often raise MK-677 during evaluations for:
- Growth hormone axis research interest
- Sleep quality discussions
- Body composition research
- Recovery research applications
A licensed provider determines clinical appropriateness individually.
Pre-PCAC July 2026 Regulatory Context
MK-677 is among the compounds under PCAC review ahead of the July 2026 meeting. Patients interested in compounded access should consult a licensed provider while it remains available.
How TelosRX Handles MK-677
TelosRX is an online-first telehealth service. Patient evaluation is asynchronous, and compounded medications are prepared through our licensed pharmacy partner.
- Step 1: Complete an asynchronous telehealth intake at TelosRX.
- Step 2: Licensed provider review.
- Step 3: Prescription issued if clinically appropriate.
- Step 4: Compounded MK-677 ships discreetly to your door.
Important Compliance Information
MK-677 is not FDA-approved. Compounded preparations are prepared under federal compounding regulations.
Prescriptions require evaluation by a licensed healthcare provider. Approval is not guaranteed. Individual results vary.
TelosRX operates under LegitScript-certified telehealth standards.
Start your private evaluation at TelosRX.